Trevi Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

TRVI$14.91-2.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Trevi Ther apeutics, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(Amounts in thousands, except share amounts)

Additional · Accumulated Other · Total
Common Stock · Paid- · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	in Capital	Income (Loss)	Deficit	Equity
Balance at March 31, 2025	99,892,915	$100	$396,669	$73	$(297,385)	$99,457
Stock-based compensation	—	—	1,384	—	—	1,384
Issuance of common stock from exercise of stock options	5,088	—	13	—	—	13
Issuance of common stock from Employee Stock Purchase Plan	15,898	—	59	—	—	59
Issuance of common stock from warrant exercise	1,851,852	2	2,535	—	—	2,537
Issuance of common stock under offering, less issuance costs	20,010,000	20	107,373	—	—	107,393
Unrealized losses on available-for-sale marketable securities	—	—	—	(49)	—	(49)
Net loss	—	—	—	—	(12,301)	(12,301)
Balance at June 30, 2025	121,775,753	$122	$508,033	$24	$(309,686)	$198,493
Balance at March 31, 2024	68,960,167	$69	$322,368	$(67)	$(250,036)	72,334
Stock-based compensation	—	—	1,127	—	—	1,127
Issuance of common stock from exercise of stock options	126,887	—	214	—	—	214
Issuance of common stock under the at-the-market sales agreement, net of commissions and allocated fees	1,474,926	2	4,832	—	—	4,834
Issuance of common stock from Employee Stock Purchase Plan	30,675	—	34	—	—	34
Issuance of common stock from pre-funded warrant exercise	1,999,262	2	(2)	—	—	—
Unrealized losses on available-for-sale marketable securities	—	—	—	(17)	—	(17)
Net loss	—	—	—	—	(12,352)	(12,352)
Balance at June 30, 2024	72,591,917	$73	$328,573	$(84)	$(262,388)	$66,174

Additional · Accumulated Other · Total
Common Stock · Paid- · Comprehensive · Accumulated · Stockholders’
	Shares	Amount	in Capital	Income (Loss)	Deficit	Equity
Balance at December 31, 2024	93,602,631	$94	$386,534	$61	$(287,045)	$99,644
Stock-based compensation	—	—	2,592	—	—	2,592
Issuance of common stock from exercise of stock options	295,372	—	731	—	—	731
Issuance of common stock from Employee Stock Purchase Plan	15,898	—	59	—	—	59
Issuance of common stock from warrant exercise	7,851,852	8	10,749	—	—	10,757
Issuance of common stock under offering, less issuance costs	20,010,000	20	107,368	—	—	107,388
Unrealized losses on available-for-sale marketable securities	—	—	—	(37)	—	(37)
Net loss	—	—	—	—	(22,641)	(22,641)
Balance at June 30, 2025	121,775,753	$122	$508,033	$24	$(309,686)	$198,493
Balance at December 31, 2023	68,283,699	$68	$321,642	$(29)	$(239,134)	$82,547
Stock-based compensation	—	—	1,850	—	—	1,850
Issuance of common stock from exercise of stock options	129,518	—	218	—	—	218
Issuance of common stock under the at-the-market sales agreement, net of commissions and allocated fees	1,474,926	2	4,832	—	—	4,834
Issuance of common stock from Employee Stock Purchase Plan	30,675	—	34	—	—	34
Issuance of common stock from pre-funded warrant exercise	2,673,099	3	(3)	—	—	—
Unrealized losses on available-for-sale marketable securities	—	—	—	(55)	—	(55)
Net loss	—	—	—	—	(23,254)	(23,254)
Balance at June 30, 2024	72,591,917	$73	$328,573	$(84)	$(262,388)	66,174

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.